Acadian Asset Management
RNAC icon

Acadian Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Acadian Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287K Buy
27,746
+4,262
+18% +$31.6K ﹤0.01% 1574
2026
Q1 		$142K Buy
+23,484
New +$167K ﹤0.01% 1673
2024
Q4 		– Sell
-1,761
Closed -$28K – 2079
2024
Q3 		$28K Buy
+1,761
New +$27.5K ﹤0.01% 1929
2023
Q2 		– Sell
-50,308
Closed -$2.1M – 1885
2023
Q1 		$2.1M Sell
50,308
-5,343
-10% -$251K 0.01% 697
2022
Q4 		$1.89M Buy
55,651
+11,110
+25% +$473K 0.01% 692
2022
Q3 		$2.19M Buy
44,541
+8,264
+23% +$454K 0.01% 613
2022
Q2 		$1.43M Buy
36,277
+30,213
+498% +$896K 0.01% 729
2022
Q1 		$222K Sell
6,064
-13,030
-68% -$815K ﹤0.01% 1189
2021
Q4 		$1.87M Sell
19,094
-8,207
-30% -$883K 0.01% 674
2021
Q3 		$3.4M Buy
27,301
+5,703
+26% +$689K 0.01% 542
2021
Q2 		$2.71M Buy
21,598
+9,330
+76% +$1.11M 0.01% 627
2021
Q1 		$1.67M Buy
+12,268
New +$1.52M 0.01% 790
2020
Q3 		– Sell
-307
Closed -$26K – 2325
2020
Q2 		$26K Buy
+307
New +$27.8K ﹤0.01% 2081
2019
Q3 		– Sell
-584
Closed -$31K – 1983
2019
Q2 		$31K Buy
+584
New +$39.8K ﹤0.01% 1551

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management's RNAC Position: Q2 2026 in Review

Acadian Asset Management increased its Cartesian Therapeutics (RNAC) stake by 18% in Q2 2026, buying an estimated $31.6K and bringing the position to 27,746 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Acadian Asset Management first reported a position in RNAC in Q2 2019 and has held it in 14 quarters since. The position peaked at $3.4M in Q3 2021. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Acadian Asset Management held 27,746 shares of Cartesian Therapeutics worth $287K as of Q2 2026.
  • Acadian Asset Management bought 4,262 Cartesian Therapeutics shares in Q2 2026, an estimated $31.6K.
  • Cartesian Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1574 holding.
  • Acadian Asset Management first reported a position in Cartesian Therapeutics in Q2 2019 and has held it in 14 quarters since.
  • Acadian Asset Management's Cartesian Therapeutics position peaked at $3.4M in Q3 2021.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.